Diaverum present at World Congress of Nephrology in Cape Town

Munich / Cape Town, 13 March 2015 – Diaverum, one of the world’s leading renal care providers, is presenting its service portfolio at the World Congress of Nephrology 2015 in Cape Town. The global provider cares for 26,000 patients in more than 300 kidney centres in Europe, Middle East/Asia, Latin America and Australia/New Zealand.

Diaverum will be present with its own booth at the exhibition offering an overview of its service portfolio at booth A05 A/B. “We are continuously expanding our reach across the world and we are looking forward to meeting nephrologists, medical staff and partners from this part of the world,” said Christina Sterner, SVP, Chief Communication & Marketing Officer Diaverum.

Diaverum has been active in world-class clinical research with a strong patient focus. During the congress Diaverum will present seven scientific posters on research related to ESRD patients treated with hemodialysis. These posters will be presented on Sunday 15th and Monday 16th March from 11:00 – 12:30 in the poster area section.

ISN’s biennial World Congress of Nephrology is a key educational event organised in collaboration with local and regional nephrology societies. In 2015 it will host 3,500 participants from more than 120 countries. The congress takes place from 13-17 March 2015 at the Cape Town International Convention Centre (CTICC).

In addition, Diaverum is sponsoring the Satellite Symposium ‘10th Conference on Kidney Disease in Disadvantaged Populations’. The meeting will focus on renal problems linked to non-communicable diseases faced by racial and ethnic minorities, indigenous and migrant populations with a focus on Africa.

“Renal diseases in disadvantaged populations are a relevant topic in many of the markets in which Diaverum is providing renal care. This issue cannot be ignored and we are taking our social responsibility seriously,” said Dr Ayman Karkar, Medical Director Area Middle East/Asia.

Press Contact

Ulrike Beringer

Corporate Communications Diaverum

E-mail: Ulrike.Beringer@diaverum.com

Phone: 49 89 45 2444 124


About Diaverum

At Diaverum, our mission is to improve the quality of life for renal patients by revitalising them both physically and emotionally. Being one of the world’s leading renal care providers, Diaverum offers a holistic approach, from preventive and early stage renal care to all renal replacement therapies. As a product independent provider — the largest in Europe — we are able to focus solely on caring for the individual needs of our patients. Our experience in renal care dates back 20 years, when the first dialysis clinic was established, previously under our former name Gambro Healthcare. Today, 8,500 employees care for 26,000 patients in 20 countries in Europe, Latin America, Middle East/Asia and Australia/New Zealand. Diaverum has its roots in Lund, Sweden and a corporate office located in Munich, Germany.

Tags:

About Us

Diaverum is a global renal care provider with a clear patient focus. The company stands for first-class healthcare, state-of-the-art education, and patient-centered research aimed at improving quality of life for renal patients. Diaverum’s experience in renal care dates back more than 25 years, when it established its first dialysis clinic in Sweden under the former name Gambro Healthcare. Today, 10,000 employees care for more than 30,000 patients in 20 countries in Europe, Latin America, Middle East, and Australia / New Zealand. Diaverum has its head office in Lund and a corporate office in Gothenburg. www.diaverum.com

Subscribe

Documents & Links

Quotes

“We are continuously expanding our reach across the world and we are looking forward to meeting nephrologists, medical staff and partners from this part of the world.”
Christina Sterner, SVP, Chief Communication & Marketing Officer Diaverum.
“Renal diseases in disadvantaged populations are a relevant topic in many of the markets in which Diaverum is providing renal care. This issue cannot be ignored and we are taking our social responsibility seriously.”
Dr Ayman Karkar, Medical Director Area Middle East/Asia